Effects of amines on percutaneous absorption of alendronate

References

• Ansel HC, Popovich NG, Allen LV. (1995). Pharmaceutical dosage forms and drug delivery systems. Malvern, USA: Williams & Wilkins.
   Google Scholar
• Aungst BJ, Blake JA, Hussain MA. (1990). Contributions of drug solubilization, partitioning, barrier disruption, and solvent permeation to the enhancement of skin permeation of various compounds with fatty acids and amines. Pharm Res, 7:712–718.
   PubMed Web of Science ®Google Scholar
• Barry BW. (1983). Dermatological formulations. New York, USA: Marcel Dekker.
   Google Scholar
• van Beek ER, Cohen LH, Leroy IM, Ebetino FH, Löwik CW, Papapoulos SE. (2003). Differentiating the mechanisms of antiresorptive action of nitrogen containing bisphosphonates. Bone, 33:805–811.
   PubMed Web of Science ®Google Scholar
• Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. (1996). Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet, 348:1535–1541.
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC et al.; Fracture Intervention Trial. (2000). Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab, 85:4118–4124.
   PubMed Web of Science ®Google Scholar
• Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ. (2000). Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone, 27:687–694.
   PubMed Web of Science ®Google Scholar
• Cheong HA, Choi HK. (2002). Enhanced percutaneous absoption of piroxicam via salt formation with ethanolamines. Pharm Res, 19:1375–1380.
   PubMed Web of Science ®Google Scholar
• Choi A, Gang H, Chun I, Gwak H. (2008). The effects of fatty acids in propylene glycol on the percutaneous absorption of alendronate across the excised hairless mouse skin. Int J Pharm, 357:126–131.
   PubMed Web of Science ®Google Scholar
• Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V et al.; Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. (2002). Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev, 23:508–516.
   PubMed Web of Science ®Google Scholar
• Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Porras AG. (1993). Clinical pharmacology of alendronate sodium. Osteoporos Int, 3 Suppl 3:S13–S16.
   PubMedGoogle Scholar
• Gur A, Colpan L, Cevik R, Nas K, Jale Sarac A. (2005). Comparison of zinc excretion and biochemical markers of bone remodelling in the assessment of the effects of alendronate and calcitonin on bone in postmenopausal osteoporosis. Clin Biochem, 38:66–72.
   PubMed Web of Science ®Google Scholar
• Hatanaka T, Kamon T, Morigaki S, Katayama K, Koizumi T. (2000). Ion pair skin transport of a zwitterionic drug, cephalexin. J Control Release, 66:63–71.
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. (2002). Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab, 87:1586–1592.
   PubMed Web of Science ®Google Scholar
• Kadono M, Kubo K, Miyazaki H, Tojyo N, Nakagawa S, Miyashita K et al. (1998). Enhanced in vitro percutaneous penetration of salicylate by ion pair formation with alkylamines. Biol Pharm Bull, 21:599–603.
   PubMed Web of Science ®Google Scholar
• Lambrinoudaki I, Christodoulakos G, Botsis D. (2006). Bisphosphonates. Ann N Y Acad Sci, 1092:397–402.
   PubMed Web of Science ®Google Scholar
• Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH et al. (1995). Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med, 333:1437–1443.
   PubMed Web of Science ®Google Scholar
• Lin JH, Chen IW, Deluna FA, Hichens M. (1992). Renal handling of alendronate in rats. An uncharacterized renal transport system. Drug Metab Dispos, 20:608–613.
   PubMed Web of Science ®Google Scholar
• Lin JH, Chen IW, Deluna FA. (1993). Uptake of alendronate by bone tissue in hypocalcemic and hypercalcemic rats. Drug Metab Dispos, 21:800–804.
   PubMed Web of Science ®Google Scholar
• Megwa SA, Cross SE, Whitehouse MW, Benson HA, Roberts MS. (2000). Effect of ion pairing with alkylamines on the in-vitro dermal penetration and local tissue disposition of salicylates. J Pharm Pharmacol, 52:929–940.
   PubMed Web of Science ®Google Scholar
• Porras AG, Holland SD, Gertz BJ. (1999). Pharmacokinetics of alendronate. Clin Pharmacokinet, 36:315–328.
   PubMed Web of Science ®Google Scholar
• Ptáček P, Klíma J, Macek J. (2002). Determination of alendronate in human urine as 9-fluorenylmethyl derivative by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci, 767:111–116.
   PubMed Web of Science ®Google Scholar
• Rodan GA, Martin TJ. (2000). Therapeutic approaches to bone diseases. Science, 289:1508–1514.
   PubMed Web of Science ®Google Scholar
• Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D et al. (2000). Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging (Milano), 12:1–12.
   PubMedGoogle Scholar
• Shakweh M, Bravo-Osuna I, Ponchel G. (2007). Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. Eur J Pharm Sci, 31:262–270.
   PubMed Web of Science ®Google Scholar
• Shargel L, Wu-pong S, Yu A. (2005). Applied Biopharmaceutics & Pharmacokinetics. New York, USA: McGraw-Hill.
   Google Scholar
• Yamada M, Uda Y, Tanigawara Y. (1987). Mechanism of enhancement of percutaneous absorption of molsidomine by oleic acid. Chem Pharm Bull, 35:3399–3406.
   PubMed Web of Science ®Google Scholar